1. Introduction

Biosimilar regulation is the body of laws, regulations, scientific standards and administrative procedures governing the development, testing, approval, manufacture, marketing, prescription and post-market monitoring of biosimilar medicines.

A biosimilar is a biological medicine that is demonstrated to be highly similar to an already approved biological medicine, known as the reference biological product, with no clinically meaningful differences in safety, purity and potency or efficacy, as applicable under the governing regulatory framework.

Biological medicines are generally produced using living cells or biological systems. Examples include monoclonal antibodies, insulin products, certain hormones, erythropoietin and therapeutic proteins. Because biological products are structurally complex and sensitive to manufacturing processes, biosimilar regulation requires more than simply comparing chemical ingredients.

The central legal question is:

How can the law permit competition and lower treatment costs while ensuring that a biosimilar is sufficiently similar, safe, effective and consistently manufactured?

The answer involves regulatory approval, comparative scientific evidence, manufacturing controls, intellectual-property protection, pharmacovigilance and judicial review.

2. Meaning and distinction between related products

Streamlining development and assessment of biosimilar medicines | European Medicines Agency (EMA)

Reference biologic

The original biological medicine licensed by a regulator, against which a proposed biosimilar is compared.

Contract Development and Manufacturing Services | HIPRA Biotech Services

Biosimilar

A separately developed biological medicine supported by evidence establishing high similarity and the absence of clinically meaningful differences under the applicable standard.

Heap of color pills and tablets on chemical formulas

Generic small-molecule medicine

Usually contains the same active ingredient as its reference drug and is assessed under a different regulatory framework, often relying on bioequivalence studies.

A biosimilar is not necessarily an exact molecular copy, and it is not automatically interchangeable with the reference product. Interchangeability and pharmacy-level substitution depend on the law of the relevant jurisdiction and, in some countries, additional regulatory requirements.

3. Legal framework for biosimilar regulation in India

India is particularly important in biosimilar regulation because it has a substantial biotechnology and pharmaceutical manufacturing sector and seeks to balance affordable access to biological medicines with patient safety and innovation.

The principal regulatory institutions are:

Central Drugs Standard Control Organization (CDSCO): India's central drug regulatory authority, responsible for regulatory assessment and permissions within its statutory jurisdiction.

Drugs Controller General of India (DCGI): The head of CDSCO, exercising relevant statutory and delegated regulatory functions.

Department of Biotechnology (DBT): Contributes scientific and biotechnology expertise to the development of regulatory standards.

State Licensing Authorities: Exercise powers assigned to them under the applicable drug laws, including relevant manufacturing and distribution licensing functions.

A. Principal legislation and guidelines

The 2025 document was expressly published for stakeholder comments on 6 May 2025. CDSCO's published notice identifies it as a draft, so it should not be treated as final law merely because it bears the year 2025. The applicable final guideline and subsequent regulatory notifications must be verified before making a compliance decision.

CDSCO+2

Official resources:

CDSCO — Biologicals and Similar Biologics

CDSCO — Guidance Documents

B. How Indian regulatory approval works

The applicant must follow the approval route applicable to its particular biological product, proposed indication, manufacturing arrangements and regulatory classification.

Step 1 — Identify the reference biologic

Establish an appropriate authorized comparator and define the intended indications.

Step 2 — Analytical and quality comparability

Compare molecular characteristics, biological activity, purity, impurities and product stability.

Step 3 — Non-clinical and clinical evidence

Submit the studies and comparative evidence required by the applicable risk-based regulatory pathway.

Step 4 — Regulatory review and authorization

Obtain the necessary permissions before lawful manufacture, import or marketing.

Step 5 — Post-marketing surveillance

Monitor adverse events, immunogenicity, product quality and manufacturing consistency.

This is a conceptual overview, not a universal checklist. The required studies and the responsible authority can differ depending on the product and the permissions being sought.

4. Core regulatory principles

4.1 Scientific similarity

The applicant must establish that the proposed biosimilar is sufficiently similar to the reference product. Regulators typically consider:

Primary amino-acid sequence and higher-order molecular structure.

Glycosylation and other post-translational modifications, where relevant.

Biological activity and mechanism of action.

Purity, impurities and degradation products.

Stability and product-related variants.

Formulation, delivery device and other clinically relevant characteristics.

Small structural differences do not automatically disqualify a product. Their significance must be assessed scientifically in the context of the product's function, safety and clinical performance.

4.2 Clinical evidence

The regulatory objective is to establish whether any residual uncertainty about safety or efficacy remains after analytical and functional comparisons.

Depending on the applicable pathway, the evidence may include pharmacokinetic and pharmacodynamic studies, immunogenicity assessments, safety data and comparative clinical studies. A full repeat of every trial conducted for the original medicine is not necessarily required.

4.3 Manufacturing quality

Biologics can be sensitive to changes in cell lines, culture conditions, purification methods, storage and transport. Consequently, a biosimilar's legal authorization depends not only on evidence from clinical studies but also on reliable, controlled manufacturing.

Applicable requirements may cover:

Good Manufacturing Practices (GMP).

Validation of manufacturing processes.

Batch testing and release specifications.

Contamination control and sterility, where applicable.

Cold-chain management and distribution.

Documentation of manufacturing changes and their effects on quality.

A product cannot be assumed to remain equivalent merely because an earlier batch satisfied quality requirements.

4.4 Pharmacovigilance and traceability

Once a biosimilar is marketed, the manufacturer and other responsible entities must comply with applicable adverse-event reporting and safety-monitoring obligations.

Product and batch traceability are particularly important where several biological medicines have similar names or where patients switch between products. Clear records help regulators identify which product was administered when a suspected adverse reaction occurs.

4.5 Naming, labeling and substitution

The product label must satisfy the applicable requirements for indications, dosage, warnings, storage, contraindications and other safety information.

Three legal questions must be kept separate:

Is the product approved as a biosimilar?

Is it approved for the particular indication in question?

Can it be substituted for another product without additional prescriber authorization?

Approval as a biosimilar does not automatically answer the third question.

5. Important Indian case laws on biosimilar regulation

Indian judicial decisions have addressed the relationship between regulatory approval, biosimilarity claims, clinical evidence, patent expiry, competition and public health. The disputes concerning trastuzumab, a monoclonal antibody used in cancer treatment, are particularly instructive.

Case 1. Genentech Inc. v. Drugs Controller General of India (Supreme Court of India, 2019–2020)

Citation: (2020) 13 SCC 371

Primary judgment: Genentech Inc. v. DCGI — judgment and case history

Facts: Genentech and related Roche entities challenged the regulatory approvals granted to Reliance Life Sciences for TrastuRel, a product represented as a biosimilar version of trastuzumab. The dispute concerned the adequacy of the required testing and the validity of the regulatory approvals. The reference product's relevant patent had expired.

Legal issues:

Whether the biosimilar had undergone the studies required by the applicable regulatory framework.

Whether regulatory approval could be challenged in civil proceedings.

Whether the manufacturer could market the product while those challenges remained unresolved.

How courts should balance patient safety, regulatory expertise and competition.

Decision and significance: The Supreme Court set aside the Delhi High Court Division Bench's interim order of 18 September 2019 and restored the operation of the Single Judge's interim directions dated 25 April 2016, while requesting expeditious disposal of the suit. It also allowed Reliance to participate in government procurement for the drug under its generic name, trastuzumab.

Indian Kanoon+1

The case is significant because it illustrates that:

Regulatory approval does not necessarily immunize a product from judicial scrutiny.

Questions about clinical testing and biosimilarity may require detailed examination of scientific and regulatory evidence.

Patent expiry does not eliminate the independent obligation to comply with drug-approval requirements.

Interim relief must account for public safety, competition and the procedural status of the dispute.

Legal principle: A biosimilar's commercial opportunity and the regulator's authorization must be assessed separately from the question of whether the product has met all applicable scientific and legal requirements.

Case 2. Roche Products (India) Pvt. Ltd. v. DCGI and connected trastuzumab proceedings (Delhi High Court, 25 April 2016)

Facts: Roche challenged products marketed by Biocon and Mylan under the names CANMAb and HERTRAZ, questioning their representations of biosimilarity to Roche's trastuzumab products. The proceedings also raised issues concerning product labeling, trademarks, the use of the reference product's data and the sufficiency of regulatory studies.

Issues: Could the competing manufacturers claim biosimilarity and refer to the innovator's product in their promotional and product materials? Were the approvals and representations consistent with the then-applicable biosimilar guidelines?

Decision: The Delhi High Court permitted the products to be marketed subject to specified restrictions, including restrictions on claims of biosimilarity with the innovator's branded products. The proceedings illustrate the distinction between using a generic or international non-proprietary name to identify a molecule and making a potentially misleading claim of equivalence to a particular branded medicine.

Indian Kanoon+1

Legal significance:

Scientific similarity claims must be supported by evidence and appropriately framed.

Trademark and passing-off disputes may arise independently of regulatory approval.

An innovator cannot rely on regulatory concerns alone to establish that every competing product infringes an intellectual-property right.

Courts may tailor interim relief to protect patients and prevent misleading representations without automatically prohibiting competition.

The ruling should be read in the context of the interim orders and subsequent proceedings; it is not a universal rule that all biosimilars must use a particular label or disclaimer.

Case 3. F. Hoffmann-La Roche Ltd. v. Drugs Controller General of India (Delhi High Court, 11–12 September 2023)

Facts: Roche challenged DCGI approvals associated with products presented as biosimilars of bevacizumab and trastuzumab. The proceedings raised allegations of deficiencies in the regulatory approval process and disputes concerning the manufacturers' right to describe their products as biosimilar medicines.

Decision and significance: In its judgment concerning the maintainability of the connected suits, the Delhi High Court rejected the applications seeking rejection of the plaints, allowing the disputes to proceed for adjudication. The decision addressed whether the pleaded challenges to the approvals and biosimilarity representations disclosed issues that could be examined in civil proceedings.

Indian Kanoon+2

The legal importance is that allegations concerning regulatory non-compliance may raise justiciable questions, depending on the statutory scheme, pleadings and relief sought. The decision should not be read as a final finding that the challenged approvals were invalid.

Case 4. Roche Products (India) Pvt. Ltd. v. Zydus Lifesciences Ltd. (Delhi High Court, 18 February 2025)

Facts: Roche brought connected proceedings involving alleged biosimilar versions of bevacizumab and trastuzumab. Among other matters, the applications concerned disclosure and production of documents relating to the disputed products.

Decision: The judgment addressed applications for discovery and production of documents under Order XI Rules 12 and 14 of the Code of Civil Procedure, 1908. It illustrates the importance of obtaining relevant manufacturing, regulatory and product-related evidence in biosimilar disputes.

Indian Kanoon

Legal significance: Biosimilar litigation may turn on technical evidence that cannot be resolved merely by comparing brand names or general product descriptions. Disclosure procedures can be important in testing the parties' factual and scientific assertions.

The precise holdings on individual disclosure requests must be taken from the full judgment; the case should not be cited as a blanket ruling that a particular biosimilar is lawful or unlawful.

6. Important international case laws

International judgments are useful for understanding regulatory competition and patent disputes, but decisions of foreign courts do not automatically bind Indian courts.

Case 5. Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017)

Court: Supreme Court of the United States.

Official judgment: Read the Supreme Court opinion

Facts: Sandoz sought approval for a biosimilar to Amgen's biological medicine under the US Biologics Price Competition and Innovation Act of 2009 (BPCIA). The parties disputed disclosure of the biosimilar application and the timing of notice before commercial marketing.

Issues:

Whether federal law permitted an injunction to enforce the statutory application-disclosure requirement.

Whether commercial-marketing notice could be provided before FDA approval.

Holding: The Supreme Court held that an injunction was not available under federal law to enforce the application-disclosure requirement at issue. It also held that notice of commercial marketing could be given before FDA licensure. The Court remanded the matter concerning potential state-law relief.

LII / Legal Information Institute+1

Legal principles:

A statutory biosimilar pathway can provide a structured mechanism for resolving patent disputes before launch.

Courts must interpret procedural requirements according to the governing statutory text.

Regulatory approval and patent litigation are separate legal questions.

The existence of a biosimilar pathway does not eliminate applicable patent rights.

Relevance to India: The judgment is persuasive comparative material on the relationship between drug regulation and patent enforcement, but the US statutory deadlines and procedures must not be imported into Indian law.

Case 6. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Federal Circuit, 2015), followed by Supreme Court review

Facts: The dispute concerned Sandoz's biosimilar application for a filgrastim product and the statutory procedure for disclosing application information and giving advance notice of commercial marketing.

Importance: The Federal Circuit's initial decision interpreted provisions of the BPCIA concerning application disclosure and notice. The Supreme Court subsequently reversed or vacated parts of the judgment in Sandoz v. Amgen in 2017, resolving the statutory notice issue differently from the Federal Circuit.

Justia Law+1

Lesson: When citing a case with a later appellate or Supreme Court history, the original ruling must be read alongside the subsequent decisions. An earlier holding cannot safely be presented as the final governing rule without that qualification.

Case 7. Amgen Inc. v. Sandoz Inc. (Federal Circuit, 14 December 2017)

Following the Supreme Court's remand, the Federal Circuit considered the remaining state-law claims and the interaction between federal biosimilar legislation and state-law remedies.

Importance: The subsequent proceedings illustrate that statutory pre-emption can restrict attempts to enforce federal biosimilar disclosure requirements through alternative state-law causes of action. The ruling is important to the allocation of responsibilities between federal regulatory legislation and state-law remedies in the United States.

Justia Law

It does not establish that every state-law claim connected with a biosimilar is pre-empted; the result depends on the claim and the governing statutory provisions.

7. Regulatory approval versus patent protection

One of the most important principles in biosimilar law is that regulatory authorization and freedom from patent infringement are distinct legal requirements.

A biosimilar may satisfy regulatory standards but still face a patent dispute. Conversely, the expiry or invalidation of a patent does not itself authorize the manufacture or sale of an unapproved biological medicine.

Indian statutory provisions to examine

A biosimilar manufacturer should consider the following provisions, as applicable:

Drugs and Cosmetics Act, 1940: statutory controls on manufacture, import, sale and distribution.

New Drugs and Clinical Trials Rules, 2019: applicable approval, study and regulatory requirements.

Patents Act, 1970: patentability, infringement, exceptions and remedies.

Trade Marks Act, 1999: protection against relevant trademark infringement and misleading use of branding.

Code of Civil Procedure, 1908: applicable procedures for interim injunctions, discovery and civil litigation.

The legal analysis must account for the specific product, its approval history, the claims made by its manufacturer and the rights asserted by any competing manufacturer.

8. Biosimilar regulation in the United States and Europe

India's framework is best understood alongside the two other major regulatory approaches.

India

Similar biologics framework

CDSCO and DBT guidelines, together with the applicable drug legislation and rules, govern the assessment of similar biologics. The relevant approval route depends on the product and applicable requirements.

CDSCO+1

United States

BPCIA framework

The Biologics Price Competition and Innovation Act of 2009 established the abbreviated biosimilar pathway under section 351(k) of the Public Health Service Act, codified at 42 U.S.C. § 262(k). The framework also addresses reference-product exclusivity and patent disputes.

Supreme Court of the United States+1

European Union

Centralized scientific framework

The European Medicines Agency and European Commission have established a scientific and legal framework for biosimilar assessment and authorization. Product-specific assessment requirements apply, and EU authorization should not be confused with automatic interchangeability or identical substitution rules in every national setting.

9. Regulatory violations and legal consequences

A biosimilar manufacturer may face regulatory or civil consequences where it breaches applicable requirements. Depending on the facts and governing law, possible consequences include:

Refusal, suspension or cancellation of authorization: Where statutory grounds and procedures permit regulatory action.

Restrictions on manufacture or marketing: For unapproved products or activities outside the scope of authorization.

Corrective or recall measures: Where product-quality or safety concerns justify intervention.

Civil injunctions and damages: Where a claimant establishes the necessary legal basis, such as infringement of an enforceable patent or trademark.

Misrepresentation claims: Where unsupported claims of similarity, misleading promotion or unlawful passing off are established.

Criminal liability: Where the conduct satisfies the elements of an applicable criminal provision, such as a relevant statutory violation involving unlawful manufacture or sale.

These consequences are not automatic. A court or regulator must establish the applicable legal grounds, follow the required procedures and consider the available defences.

10. Emerging legal and policy challenges

A. Interchangeability and substitution

Regulators and policymakers must determine when switching between a reference biologic and a biosimilar can be permitted safely. Scientific similarity, regulatory approval and pharmacy-level substitution are related but distinct concepts.

B. Extrapolation of indications

A biosimilar may be proposed for more than one indication of the reference product. Whether additional indications can be authorized without separate clinical trials depends on the scientific justification, mechanism of action, available evidence and applicable regulatory requirements.

C. Immunogenicity and long-term safety

Biological medicines may provoke immune responses. Post-marketing monitoring is important because uncommon or delayed safety issues may not be apparent in pre-approval studies.

D. Competition and access to medicines

Biosimilars can increase competition and improve access to expensive treatments. Excessively restrictive practices may impede competition, while insufficient scientific oversight can compromise public health.

E. Confidential manufacturing information

Manufacturers may need to protect commercially sensitive information while supplying sufficient evidence to regulators and complying with lawful disclosure orders. The applicable confidentiality rules and procedures determine what information may be disclosed and to whom.

11. Practical legal-compliance checklist

For a company planning to develop or market a biosimilar in India, the following questions provide a starting point.

Compliance review

0 of 9

Identify the applicable regulatory pathway and authorized reference product.

Confirm the currently operative guidelines, rules and required permissions.

Complete the analytical, functional and comparative studies required for the product.

Validate the manufacturing process, quality controls and batch-release procedures.

Establish compliance with applicable clinical-trial and ethics requirements.

Review the proposed indications, label, product name and promotional claims.

Assess patents, trademarks and other relevant intellectual-property rights.

Implement pharmacovigilance, adverse-event reporting and traceability systems.

Verify import, manufacturing, distribution and storage permissions as applicable.

Copy checklist

This checklist is a planning aid, not a substitute for a product-specific regulatory assessment.

12. Conclusion

Biosimilar regulation is a multidisciplinary field at the intersection of pharmaceutical law, biotechnology, administrative law, intellectual-property law and public health.

The principal legal principles are:

A biosimilar must satisfy the applicable scientific and regulatory standards before marketing.

Approval depends on evidence of similarity, product quality and the absence of clinically meaningful differences under the relevant framework.

Manufacturing controls and post-marketing safety monitoring remain important after authorization.

Regulatory approval, patent freedom, trademark compliance and substitution rights must be analyzed separately.

Indian litigation involving trastuzumab and bevacizumab demonstrates the importance of regulatory scrutiny, scientific evidence, procedural fairness and access to medicines.

Foreign cases such as Sandoz v. Amgen provide comparative guidance but do not replace Indian legislation or binding Indian judicial precedent.

For Indian legal research, the most useful starting points are the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, the applicable CDSCO–DBT Similar Biologics Guidelines, and the Supreme Court's decision in Genentech Inc. v. Drugs Controller General of India.

Scope note: This is a general legal and academic explanation, not a product-specific regulatory opinion. The operative version of any guideline, subsequent judicial history and applicable product-specific requirements should be checked before relying on the analysis in a filing, litigation or marketing-authorization application.